Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 ...

SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, ...

Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. Now the FDA has ...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...

WESTBROOK, ME - JANUARY 4: IDEXX Laboratories has been added to the Standard & Poor's 500 Index. (Photo by Ben McCanna/Portland Portland Press Herald via Getty Images) IDEXX Laboratories’ (IDXX) ...

Washington | Hearing implant pioneer Cochlear and sleep therapeutics giant ResMed have urged the Trump administration to spare their devices from tariffs, arguing vulnerable patients would be harmed, ...

Macquarie sees ResMed's recent quarterly performance as solid, with revenue and margins aligning well with expectations, thanks to gains in manufacturing and logistics. The company's outlook remains ...

ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of ...

ResMed posted a 9% revenue increase and an 11% rise in net income for the September quarter, driven by increased demand for sleep treatment products. The company demonstrated strong growth in various ...

ResMed’s 2030 strategy focuses on empowering 500 million lives by the end of the decade through its digital health products and cloud-based software solutions. The company reported that it has already ...

ResMed Inc. reported its Q4 2025 earnings, revealing a robust financial performance with revenue reaching $1.35 billion, surpassing the forecast of $1.33 billion. Despite this positive financial ...

ResMed has seen its fair value estimate edge up slightly from $291.86 to $295.13, as recent improvements in margin expectations have contributed to this change. This modest increase comes amid ongoing ...